The complex genetic aetiology of multiple sclerosis

Journal of NeuroVirology

Volumn 6, Issue SUPPL. 2, 2000, Pages

  Oksenberg, Jorge R ^a   Barcellos, Lisa F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Automunity; Genetics; Major histocompatibility complex; Multiple sclerosis

Indexed keywords

MYELIN;

CHROMOSOME ANALYSIS; CONFERENCE PAPER; DIZYGOTIC TWINS; GENE LOCUS; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME; HUMAN; IMMUNE RESPONSE; INHERITANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOZYGOTIC TWINS; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; SIBLING;

HUMANS; MULTIPLE SCLEROSIS; MYELIN PROTEINS;

EID: 0034077486     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Alter M, Leibowitz U, Speer J (1996). Risk of multiple sclerosis related to age at migration to Israel. Arch Neurol 15: 234-237.
2. Bachmann S, Kesselring J (1998). Multiple sclerosis and infectious childhood diseases. Neuroepidemiol 17: 154-160.
3. Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison W, McFarland HF, Trent JM (1998). Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA 95: 9979-9984.
4. Cantorna MT, Hayes CE, DeLuca HF (1996). 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 93: 7861-7864.
5. Chataway J, Feakes R, Coraddu F, Gray J, Deans J, Fraser M, Robertson N, Broadley S, Jones H, Clayton D, Goodfellow P, Sawcer S, Compston A (1998). The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systemic genome screen. Brain 121: 1869-1887.
6. Cippitelli M, Santoni A (1998). Vitamin D3: a transcriptional modulator of the interferongamma gene. Eur J Immunol 28: 3017-3030.
7. Compston A (1997). Genetic epidemiology of multiple sclerosis. J Neurol Neurosurg Psych 62: 553-561.
8. Cosman F, Nieves J, Komar L (1998). Fracture history and bone loss in patients with MS. Neurol 51: 1161-1165.
9. Dalgleish AG (1997). Viruses and multiple sclerosis. Acta Neurol Scand 169 (Suppl): 8-15.
10. Dean G, Kurtzke JF (1971). On the risk of multiple sclerosis according to age at migration to South Africa. Br Med J 3: 725-729.
11. Ebers GC, Sadovnick AD, Risch NJ, The Canadian Collaborative Study Group (1995). A genetic basis for familial aggregation in MS. Nature 377: 150-151.
12. Ebers GC, Sadovnick AD (1994). The role of genetic factors in multiple sclerosis susceptibility. J Neuroimmunol 54: 1-17.
13. Ebers GC, Kukay K, Bulman DE, Sadovnick AD, Rice G, Anderson C, Armstrong H, Cousin K, Bell RB, Hader W, Paty DW, Hashimoto S, Oger J, Duquette P, Warren S, Gray T, O'Connor P, Nath A, Auty A, Metz L, Francis G, Paulseth JE, Murray TJ, Pryse-Phillips W, Nelson R, Freedman M, Brunet D, Bouchard J-P, Hinds D, Risch N (1996). A full genome search in multiple sclerosis. Nature Genet 13: 472-476.
14. Gale CR, Martyn CN (1995). Migrant studies in multiple sclerosis. Prog Neurobiol 47: 425-448.
15. Granieri E, Casetta I (1997). Selected reviews common childhood and adolescent infections and multiple sclerosis. Neurology 49: S42-S54.
16. Hogancamp WE, Rodriguez M, Weinshenker BG (1997). The epidemology of multiple sclerosis. Mayo Clin Proc 72: 871-878.
17. Issa LL, Leong GM, Eisman JA (1998). Molecular mechanism of vitamin D receptor action. Inflamm Res 47: 451-475.
18. Karpuj M, Oksenberg JR, Steinman L (1997). Multiple sclerosis: a polygenic disease involving epistatic interactions, germline rearrangements and environmental effects. Neurogenet 1: 21-28.
19. Kuokkanen S, Gschwend M, Rioux JD, Daly MJ, Terwilliger JD, Tienari PJ, Wikstrom J, Palo J, Stein LD, Hudson TJ, Lander ES, Peltonen L (1997). Genomewide scan of multiple sclerosis in Finnish multiplex families. Am J Hum Genet 61: 1379-1387.
20. Kurtzke JF, Hyllested K (1979). Multiple sclerosis in the Faroe Islands: 1. Clinical and epidemiological features. Ann Neurol 5: 6-21.
21. Kurtzke JF (1980). Epidemiological contribution to multiple sclerosis. An overview. Neurol 30 (Suppl 2): 61-79.
22. Kurtzke JF, Delasnerie-Laupretre N (1996). Reflection on the geographic distribution of multiple sclerosis in France. Acta Neurol Scand 93: 110-117.
23. Lauer K (1997). Diet and multiple sclerosis. Neurol 49 (suppl): 55-61.
24. Lewis CM, Wise LH, Lanchburry JS (1998). Meta-analysis of genome search results. Am J Hum Genet 63: A1351.
25. Martyn CN, Gale CR (1997). The epidemiology of multiple sclerosis. Acta Neurol Scand 169 (suppl): 3-7.
26. Milanov I, Topalov N, Kmetski T (1999). Prevalence of multiple sclerosis in Gypsies and Bulgarians. Epidemiol 18: 218-222.
27. Mumford CJ, Wood NW, Kellar-Wood H, Thorpe J, Miller D, Compston DAS (1994). The British Isles survey of multiple sclerosis in twins. Neurol 44: 11-15.
28. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R (1994). High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurol 44: 1687-1692.
29. Oksenberg JR, Seboun E, Hauser SL (1996). Genetics of demyelinating diseases. Brain Pathol 6: 289-302.
30. Olerup O, Hillert J (1991). HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 38: 1-15.
31. Poser CM (1995). Viking voyages: the origin of multiple sclerosis? An essay in medical history. Acta Neurol Scand 161 (Suppl): 11-22.
32. Risch N (1992). Corrections to linkage strategies for genetically complex traits. III. The effect of marker polymorphism on analysis of affected relative pairs. Am J Hum Genet 51: 673-675.
33. Sadovnick AD, Armstrong H, Rice GPA, Bulman D, Hashimoto L, Paty DW, Hashimoto SA, Warren S, Hader W, Murray TJ (1993). A population-based study of multiple sclerosis in twins: update. Ann Neurol 33: 281-285.
34. Sadovnick AD, Ebers GC, Dyment DA, Risch NJ and the Canadian Collaborative Study Group (1996). Evidence for genetic basis of multiple sclerosis. Lancet 347: 1728-1730.
35. Sawcer S, Jones HB, Feakes R, Gray J, Smaldon N, Chataway J, Robertson N, Clayton D, Goodfellow PN, Compston A (1996). A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nature Genet 13: 464-468.
36. Schrijver HM, Crusius JB, Uitdehaag BM, Garcia Gonzalez MA, Kostense PJ, Polman CH, Pena AS (1999). Association of interleukin-1 beta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurol 52: 595-599.
37. Sciacca FL, Ferri C, Vandenbroeck K, Vegli F, Gobbi C, Martrinelli F, Franciotta D, Zaffaroni M, Marrosu M, Martinelli V, Comi G, Canal D, Grimaldi LM (1999). Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurol 10: 1896-1898.
38. Seboun E, Oksenberg JR, Hauser SL (1996). Molecular genetics of multiple sclerosis. In: The molecular and genetic basis of neurological disease, 2nd edition. Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, Kunkel LM (eds). Butterworth-Heinemann: Boston, pp 631-662.
39. The Multiple Sclerosis Genetics Group (1996). A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. Nature Genet 13: 469-471.
40. The Multiple Sclerosis Genetics Group (1998). Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. Hum Molec Genet 7: 1229-1234.